| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.2 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | -0.062 | 0.2 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.091 | 0.2 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | 0.064 | 0.2 |
| mRNA | BRD-K35604418 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |